Medy-Tox clinical trials
The registry lists 52 studies whose lead sponsor is Medy-Tox or the company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 9, 2024.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 52studies on the registry
- 0open to participants now
What it is testing
The drugs Medy-Tox’s studies test, most studies first; none is open now — 4 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- botulinum toxin type A12 in phase 30 open · 24
- nivobotulinumtoxina5 in phase 30 open · 7
- coretox2 in phase 30 open · 4
- MT9211 in phase 30 open · 3
All 52 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed5096%
- Status unknown or other24%
Over the years
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 1418
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Medy-Tox.
- Medy-Tox49 studiesSame company
Something wrong?
- Medytox Korea3 studies →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 52. Browse all 52 →
- MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)CompletedNCT04157686Phase 3
- Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar LinesCompletedNCT01485601Phase 2
- Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar LinesCompletedNCT05321979Phase 3
Sponsor listed in the registry: Medytox Korea
- MT10109L in the Treatment of Lateral Canthal LinesCompletedNCT03785145Phase 3
- MT10109L in the Treatment of Glabellar LinesCompletedNCT03795922Phase 3
- MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar LinesCompletedNCT03732833Phase 3
- MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)CompletedNCT03721016Phase 3
- A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar LinesCompletedNCT05217355Phase 2
Sponsor listed in the registry: Medytox Korea
- Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental FatCompletedNCT05195112Phase 3
- Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar LinesCompletedNCT05059587Phase 3
Sponsor listed in the registry: Medytox Korea
- CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)CompletedNCT05164003Phase 1
- CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)CompletedNCT03289702Phase 3
- Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-FaceCompletedNCT03754413Not applicable
- Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar LinesCompletedNCT04143815Phase 2
- Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal LinesCompletedNCT04143854Phase 2
- Neuramis® Volume Lidocaine Treatment in Patients With Loss of Mid-face VolumeCompletedNCT02721368Not applicable
- Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar LinesCompletedNCT03289169Phase 4
- Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®CompletedNCT03796351Phase 1
- Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy SubjectsCompletedNCT03905291Phase 1
- Pivotal Clinical Study to Assess the Anti-adhesive Effect and Safety of ABT13107 Applied to Postoperative IntrauterineCompletedNCT04007211Not applicable
- Observational Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile EnhancementCompletedNCT04496427
- A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental FatCompletedNCT04144049Phase 2
- The Efficacy and Safety of Repeat-dose Potenfill for Temporary Penile EnhancementCompletedNCT03840070Not applicable
- The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar LinesCompletedNCT03837561Phase 3
- Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive BladderStatus unknownNCT04113941Phase 3
- Neuramis® Deep Lidocaine Compared to YVOIRE® Volume Plus for Correction of Nasolabial FoldsCompletedNCT03753152Not applicable
- Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight SubjectCompletedNCT03759743Not applicable
- Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®Status unknownNCT04281745Phase 4
- MEDITOXIN® Treatment in Subject With Benign Masseteric HypertrophyCompletedNCT03452345Phase 3
- Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary HyperhidrosisCompletedNCT03760198Phase 3
- Efficacy and Safety Study of MT10107 in the Treatment of Glabella LineCompletedNCT03908008Phase 3
- MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb SpasticityCompletedNCT03908580Phase 4
- Efficacy and Safety of MEDITOXIN® in Cervical DystoniaCompletedNCT03905304Phase 3
- Efficacy and Safety Study of Neuramis in Correction of Nasolabial FoldCompletedNCT01585220Phase 3
- Meditoxin® Treatment in Patients With Post Stroke Upper Limb SpasticityCompletedNCT02757404Phase 4
- MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb SpasticityCompletedNCT01313767Phase 3
- Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)CompletedNCT03894748Phase 2/3
- Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar LinesCompletedNCT01237977Phase 3
- Meditoxin® Treatment in Patients With Cervical DystoniaCompletedNCT03232320Phase 3
- MEDITOXIN® in Treatment of Crow's Feet LineCompletedNCT03317574Phase 3
- Medytoxin® Treatment in Patients With Benign Masseteric HypertrophyCompletedNCT02292472Phase 2
- Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male VolunteersCompletedNCT03317717Phase 1
- The Efficacy and Safety of MEDITOXIN® in Children With Cerebral PalsyCompletedNCT01256021Phase 4
- Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive BladderCompletedNCT03371342Phase 1
- Anhidrotic Area and Safety of MEDITOXIN in Healthy Male ValunteersCompletedNCT03647982Phase 1
- Pharmacodynamic and Safety of MBA-P01 in Healthy Male VolunteersCompletedNCT03547141Phase 1
- Efficacy and Safety of Potenfill for Temporary Penile EnhancementCompletedNCT03512717Not applicable
- Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential BlepharospasmCompletedNCT03216473Phase 3
- Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar LinesCompletedNCT03216408Phase 3
- Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial FoldCompletedNCT02751034Phase 3